ENVERIC BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
ENVERIC BIOSCIENCES, INC. (ENVB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 25.50 thousand shares for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-26.
Discontinued › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2024-03-26
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-12-31 was -77.52K shares.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2016-12-31 was -915.66K shares.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2016-09-30 was 214.50K shares.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2016-06-30 was 655.50K shares.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 25.50K shares, a 927.40% increase from fiscal 2021.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 2.48K shares, a 99.34% decline from fiscal 2020.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2020 was 378.80K shares, a 15.58% decline from fiscal 2019.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2019 was 448.71K shares, a 459.81% increase from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | 25.50K shares 10-K · filed 2024-03-26 | ||||
| 2021-12-31 | -77.52K shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-09 | 2.48K shares 10-K/A · filed 2023-06-09 | 124.10K shares 10-K · filed 2022-03-31 | ||
| 2021-09-30 | 80.00K shares 10-Q · filed 2021-11-15 | ||||
| 2020-12-31 | 378.80K shares 10-K · filed 2022-03-31 | ||||
| 2019-12-31 | 448.71K shares 10-K · filed 2021-04-01 | 0.00 shares 10-K/A · filed 2020-08-12 | |||
| 2018-12-31 | 80.16K shares 10-K/A · filed 2020-08-12 | ||||
| 2017-12-31 | 22.39K shares 10-K/A · filed 2020-08-12 | ||||
| 2016-12-31 | -915.66K shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-08-12 | -701.16K shares derived: sum of 2 quarters · filed 2020-08-12 | -45.66K shares derived: sum of 3 quarters · filed 2020-08-12 | 59.34K shares 10-K/A · filed 2020-08-12 | 975.70K shares 10-K/A · filed 2017-04-04 |
| 2016-09-30 | 214.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | 870.00K shares derived: sum of 2 quarters · filed 2016-11-14 | 975.00K shares 10-Q · filed 2016-11-14 | ||
| 2016-06-30 | 655.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-12 | 760.50K shares 10-Q · filed 2016-08-12 | |||
| 2016-03-31 | 105.00K shares 10-Q · filed 2016-05-16 | ||||
| 2015-12-31 | 150.00K shares 10-KT · filed 2016-03-15 | 9.33K shares 10-K/A · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |